British Journal of Cancer - Table of Contents alert Volume 113 Issue 11

If you are unable to see the message below, click here to view.

TABLE OF CONTENTS Volume 113, Issue 11 (1529-1643) Published online 1 December 2015 In this issue Minireview Clinical Studies Translational Therapeutics Molecular Diagnostics Epidemiology Letters to the Editor Corrigenda Also new today Advance online publication Digital Edition Sign up for e-alerts Recommend to your library Web feed Subscribe Advertisement Introducing THE DARWIN CANCER BLOG -"keeping an evolutionary eye on cancer" led by Prof. Mel Greaves and brought to you by BJC. This blog provides a forum for discussing how an evolutionary perspective is changing thinking about cancer and aims to encourage discussion and debate among specialists and general interest readers. »Start reading the latest content   Minireview Top Interactions between Myc and MondoA transcription factors in metabolism and tumourigenesis Blake R Wilde and Donald E Ayer Br J Cancer 2015 113: 1529-1533; advance online publication, October 15, 2015; 10.1038/bjc.2015.360 Abstract | Full Text Clinical Studies Top A phase I combination dose-escalation study of eribulin mesylate and gemcitabine in patients with advanced solid tumours: a study of the Princess Margaret Consortium S Lheureux, A M Oza, S A Laurie, R Halford, D Jonker, E Chen, D Keller, V Bourade, L Wang, L Doyle, L L Siu and R Goel Br J Cancer 2015 113: 1534-1540; advance online publication, November 10, 2015; 10.1038/bjc.2015.343 Abstract | Full Text Complications of hyperglycaemia with PI3K–AKT–mTOR inhibitors in patients with advanced solid tumours on Phase I clinical trials E Geuna, D Roda, S Rafii, B Jimenez, M Capelan, K Rihawi, F Montemurro, T A Yap, S B Kaye, J S De Bono, L R Molife and U Banerji Br J Cancer 2015 113: 1541-1547; advance online publication, November 10, 2015; 10.1038/bjc.2015.373 Abstract | Full Text Phase I trial of EpCAM-targeting immunotoxin MOC31PE, alone and in combination with cyclosporin Y Andersson, O Engebraaten, S Juell, S Aamdal, P Brunsvig, Ø Fodstad and S Dueland Br J Cancer 2015 113: 1548-1555; advance online publication, November 10, 2015; 10.1038/bjc.2015.380 Abstract | Full Text Histopathological features of papillary thyroid carcinomas detected during four screening examinations of a Ukrainian-American cohort Tetiana I Bogdanova, Liudmyla Yu Zurnadzhy, Yuri E Nikiforov, Rebecca J Leeman-Neill, Mykola D Tronko, Stephen Chanock, Kiyohiko Mabuchi, Ilya A Likhtarov, Leonila M Kovgan, Vladimir Drozdovitch, Mark P Little, Maureen Hatch, Lydia B Zablotska, Viktor M Shpak, Robert J McConnell and Alina V Brenner Br J Cancer 2015 113: 1556-1564; advance online publication, December 3, 2015; 10.1038/bjc.2015.372 Abstract | Full Text Diagnosis of pathological complete response to neoadjuvant chemotherapy in breast cancer by minimal invasive biopsy techniques Joerg Heil, Sherko Kümmel, Benedikt Schaefgen, Stefan Paepke, Christoph Thomssen, Geraldine Rauch, Beyhan Ataseven, Regina Große, Volker Dreesmann, Thorsten Kühn, Sibylle Loibl, Jens-Uwe Blohmer and Gunter von Minckwitz Br J Cancer 2015 113: 1565-1570; advance online publication, November 10, 2015; 10.1038/bjc.2015.381 Abstract | Full Text Translational Therapeutics Top Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients Frede Donskov, M Dror Michaelson, Igor Puzanov, Mellar P Davis, Georg A Bjarnason, Robert J Motzer, David Goldstein, Xun Lin, Darrel P Cohen, Robin Wiltshire and Brian I Rini Br J Cancer 2015 113: 1571-1580; advance online publication, October 22, 2015; 10.1038/bjc.2015.368 Abstract | Full Text Molecular Diagnostics Top Prognostic value of interleukin-6 and interleukin-6 receptor in organ-confined clear-cell renal cell carcinoma: a 5-year conditional cancer-specific survival analysis Qiang Fu, Yuan Chang, Huimin An, Hangcheng Fu, Yu Zhu, Le Xu, Weijuan Zhang and Jiejie Xu Br J Cancer 2015 113: 1581-1589; advance online publication, November 10, 2015; 10.1038/bjc.2015.379 Abstract | Full Text Pancreatic preneoplastic lesions plasma signatures and biomarkers based on proteome profiling of mouse models Laetitia Ligat, Nathalie Saint-Laurent, Aïcha El-Mrani, Véronique Gigoux, Talal Al Saati, Richard Tomasini, Jérémy Nigri, Sébastien Dejean, Frédéric Pont, Romain Baer, Julie Guillermet-Guibert, Pierre Cordelier, Frédéric Lopez and Marlène Dufresne Br J Cancer 2015 113: 1590-1598; advance online publication, October 29, 2015; 10.1038/bjc.2015.370 Abstract | Full Text Epidemiology Top Sexual healthcare professionals’ views on HPV vaccination for men in the UK Tom Nadarzynski, Helen E Smith, Daniel Richardson, Elizabeth Ford and Carrie D Llewellyn Br J Cancer 2015 113: 1599-1601; advance online publication, November 17, 2015; 10.1038/bjc.2015.403 Abstract | Full Text Age as an independent prognostic factor for survival of localised synovial sarcoma patients Myrella Vlenterie, Vincent K Y Ho, Suzanne E J Kaal, Richelle Vlenterie, Rick Haas and Winette T A van der Graaf Br J Cancer 2015 113: 1602-1606; advance online publication, November 10, 2015; 10.1038/bjc.2015.375 Abstract | Full Text New-onset type 2 diabetes, elevated HbA1c, anti-diabetic medications, and risk of pancreatic cancer Yunxia Lu, Luis Alberto García Rodríguez, Linnéa Malgerud, Antonio González-Pérez, Mar Martín-Pérez, Jesper Lagergren and Tomas S Bexelius Br J Cancer 2015 113: 1607-1614; advance online publication, November 17, 2015; 10.1038/bjc.2015.353 Abstract | Full Text Magnesium intake and incidence of pancreatic cancer: the VITamins and Lifestyle study Daniel Dibaba, Pengcheng Xun, Kuninobu Yokota, Emily White and Ka He Br J Cancer 2015 113: 1615-1621; advance online publication, November 10, 2015; 10.1038/bjc.2015.382 Abstract | Full Text Reproductive factors and epithelial ovarian cancer survival in the EPIC cohort study Jelena Bešević, Marc J Gunter, Renée T Fortner, Konstantinos K Tsilidis, Elisabete Weiderpass, N Charlotte Onland-Moret, Laure Dossus, Anne Tjønneland, Louise Hansen, Kim Overvad, Sylvie Mesrine, Laura Baglietto, Françoise Clavel-Chapelon, Rudolf Kaaks, Krasimira Aleksandrova, Heiner Boeing, Antonia Trichopoulou, Pagona Lagiou, Christina Bamia, Giovanna Masala, Claudia Agnoli, Rosario Tumino, Fulvio Ricceri, Salvatore Panico, HB(as) Bueno-de-Mesquita, Petra H Peeters, Mie Jareid, J Ramón Quirós, Eric J Duell, María-José Sánchez, Nerea Larrañaga, María-Dolores Chirlaque, Aurelio Barricarte, Joana A Dias, Emily Sonestedt, Annika Idahl, Eva Lundin, Nicholas J Wareham, Kay-Tee Khaw, Ruth C Travis, Sabina Rinaldi, Isabelle Romieu, Elio Riboli and Melissa A Merritt Br J Cancer 2015 113: 1622-1631; advance online publication, November 10, 2015; 10.1038/bjc.2015.377 Abstract | Full Text Letters to the Editor Top Comment on: ‘Trends in the lifetime risk of developing cancer in great Britain: comparison of risk for those born from 1930 to 1960’—cancer predictions need more context J L Oke, B D Nicholson and B Shinkins Br J Cancer 2015 113: 1632; advance online publication, June 23, 2015; 10.1038/bjc.2015.219 Full Text Comment on ‘Dexamethasone exerts profound immunologic interference on treatment efficacy for recurrent glioblastoma’ Susannah Ellsworth and Stuart A Grossman Br J Cancer 2015 113: 1632-1633; advance online publication, September 8, 2015; 10.1038/bjc.2015.317 Full Text Response to: Comment on ‘Dexamethasone exerts profound immunologic interference on treatment efficacy for recurrent glioblastoma’ Eric T Wong and Kenneth D Swanson Br J Cancer 2015 113: 1633-1634; advance online publication, September 8, 2015; 10.1038/bjc.2015.320 Full Text BRAF-mutated metastatic colorectal cancer between past and future Chiara Cremolini, Massimo Di Maio, Fausto Petrelli, Rosa Berenato, Fotios Loupakis and Filippo Pietrantonio Br J Cancer 2015 113: 1634-1635; advance online publication, September 10, 2015; 10.1038/bjc.2015.316 Full Text Reply: Comment on ‘Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal-antibody therapy for RAS wild-type metastatic colorectal cancer’ Andrew Rowland, Mafalda M Dias, Michael D Wiese, Ganessan Kichenadasse, Ross A McKinnon, Christos S Karapetis and Michael J Sorich Br J Cancer 2015 113: 1635; advance online publication, September 10, 2015; 10.1038/bjc.2015.325 Full Text Comment on: ‘KRAS and BRAF mutations are prognostic biomarkers in patients undergoing lung metastasectomy of colorectal cancer.’ Variation in survival associated with proto-oncongenes is not evidence for effectiveness of lung metastasectomy Giuseppe Cardillo, Sahar Mokhles, Norman Williams, Fergus Macbeth, Christopher Russell and Tom Treasure Br J Cancer 2015 113: 1636; advance online publication, September 15, 2015; 10.1038/bjc.2015.331 Full Text Reply: Comment on ‘KRAS and BRAF mutations are prognostic biomarkers in patients undergoing lung metastasectomy of colo-rectal cancer’ Stéphane Renaud, Pierre-Emmanuel Falcoz, Benoit Romain, Anne Olland, Nicola Santelmo, Cécile Brigand, Serge Rohr, Dominique Guenot and Gilbert Massard Br J Cancer 2015 113: 1637-1638; advance online publication, September 15, 2015; 10.1038/bjc.2015.330 Full Text Is it the creatine or the anabolic androgenic steroids? Need for assessing the steroids role in testicular cancer Patrick Cazorla-Saravia and Reneé Pereyra-Elías Br J Cancer 2015 113: 1638; advance online publication, August 11, 2015; 10.1038/bjc.2015.294 Full Text Comment on ‘Impact of intra-arterial chemotherapy including internal carotid artery for advanced paranasal sinus cancers involving the skull base’ Paolo Bossi, Ester Orlandi and Lisa Licitra Br J Cancer 2015 113: 1638-1639; advance online publication, August 11, 2015; 10.1038/bjc.2015.293 Full Text Corrigenda Top Hypermethylation of the 5′ CpG island of the gene encoding the serine protease Testisin promotes its loss in testicular tumorigenesis K J Manton, M L Douglas, S Netzel-Arnett, D R Fitzpatrick, D L Nicol, A W Boyd, J A Clements and T M Antalis Br J Cancer 2015 113: 1640; 10.1038/bjc.2015.384 Full Text Exogenous administration of protease-resistant, non-matrix-binding IGFBP-2 inhibits tumour growth in a murine model of breast cancer C-L Soh, K McNeil, C M Owczarek, M P Hardy, L J Fabri, M Pearse, C A Delaine and B E Forbes Br J Cancer 2015 113: 1640; 10.1038/bjc.2015.385 Full Text Ethnicity, deprivation and screening: survival from breast cancer among screening-eligible women in the West Midlands diagnosed from 1989 to 2011 M Morris, L M Woods, N Rogers, E O’Sullivan, O Kearins and B Rachet Br J Cancer 2015 113: 1640; 10.1038/bjc.2015.386 Full Text HLA class I is most tightly linked to levels of tapasin compared with other antigen-processing proteins in glioblastoma Camilla Thuring, Elna Follin, Linda Geironson, Eva Freyhult, Victoria Junghans, Mikkel Harndahl, Søren Buus and Kajsa M Paulsson Br J Cancer 2015 113: 1640; 10.1038/bjc.2015.387 Full Text PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas Jonathan D Black, Salvatore Lopez, Emiliano Cocco, Stefania Bellone, Gary Altwerger, Carlton L Schwab, Diana P English, Elena Bonazzoli, Federica Predolini, Francesca Ferrari, Elena Ratner, Dan-Arin Silasi, Masoud Azodi, Peter E Schwartz and Alessandro D Santin Br J Cancer 2015 113: 1641; 10.1038/bjc.2015.388 Full Text Benzene exposure and risk of lymphohaematopoietic cancers in 25 000 offshore oil industry workers J S Stenehjem, K Kjærheim, M Bråtveit, S O Samuelsen, F Barone-Adesi, N Rothman, Q Lan and T K Grimsrud Br J Cancer 2015 113: 1641; 10.1038/bjc.2015.390 Full Text Tumour expression of leptin is associated with chemotherapy resistance and therapy-independent prognosis in gastro-oesophageal adenocarcinomas G H Bain, E Collie-Duguid, G I Murray, F J Gilbert, A Denison, F Mckiddie, T Ahearn, I Fleming, J Leeds, P Phull, K Park, S Nanthakumaran, H I Grabsch, P Tan, A Welch, L Schweiger, A Dahle-Smith, G Urquhart, M Finegan, K M Matula and R D Petty Br J Cancer 2015 113: 1641; 10.1038/bjc.2015.391 Full Text Comment on ‘Are the studies on cancer risk from CT scans biased by indication? Elements of answer from a large-scale cohort study in France’ – Evidence of confounding by predisposing factors unclear E Cardis and M Bosch de Basea Br J Cancer 2015 113: 1641; 10.1038/bjc.2015.393 Full Text Dexamethasone exerts profound immunologic interference on treatment efficacy for recurrent glioblastoma E T Wong, E Lok, S Gautam and K D Swanson Br J Cancer 2015 113: 1642; 10.1038/bjc.2015.404 Full Text Granulocyte colony-stimulating factor receptor signalling via Janus kinase 2/signal transducer and activator of transcription 3 in ovarian cancer J Kumar, F W Fraser, C Riley, N Ahmed, D R McCulloch and A C Ward Br J Cancer 2015 113: 1642-1643; 10.1038/bjc.2015.389 Full Text Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to British Journal of Cancer. In order to do so, please purchase a subscription. You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Nature Publishing Group |One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2015 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.